INT267145

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 4.12
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ICAM1) cell adhesion (ICAM1) plasma membrane (ICAM1)
Anatomy Link Frequency
T cells 4
plaques 2
ICAM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 82 97.56 Very High Very High Very High
psoriasis 101 83.20 Quite High
corticosteroid 2 42.92 Quite Low
Inflammatory response 10 41.76 Quite Low
Angina 6 12.00 Low Low
Infliximab 60 5.00 Very Low Very Low Very Low
Etanercept 46 5.00 Very Low Very Low Very Low
cytokine 24 5.00 Very Low Very Low Very Low
Adalimumab 22 5.00 Very Low Very Low Very Low
Nicotine 20 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 192 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 32 100.00 Very High Very High Very High
INFLAMMATION 94 97.56 Very High Very High Very High
Psoriasis 126 97.24 Very High Very High Very High
Disease 82 96.00 Very High Very High Very High
Nicotine Addiction 366 78.00 Quite High
Autoimmune Disease 3 70.24 Quite High
Multiple Organ Failure 2 54.72 Quite High
Pruritus 1 54.20 Quite High
Viral Meningitis 1 53.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Efalizumab inhibits T-cell activation, cutaneous trafficking, and adhesion to keratinocytes through the blockade of LFA-1/ICAM-1 binding, steps in the immunologic cascade that lead to the formation of the psoriatic plaques (Menter et al 2005).
Negative_regulation (blockade) of ICAM-1 Binding (binding) of in plaques associated with psoriasis and adhesions
1) Confidence 0.57 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727906 Disease Relevance 0.74 Pain Relevance 0.07
Thus a causative link between sICAM-1 and vascular disease has yet to be firmly established.
Negative_regulation (established) of sICAM-1 Binding (link) of associated with increased venous pressure under development
2) Confidence 0.36 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669563 Disease Relevance 1.37 Pain Relevance 0.10
Thus a causative link between sICAM-1 and vascular disease has yet to be firmly established.
Negative_regulation (established) of sICAM-1 Binding (link) of associated with increased venous pressure under development
3) Confidence 0.36 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671531 Disease Relevance 1.37 Pain Relevance 0.10
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
Negative_regulation (blocking) of intercellular adhesion molecule 1 Binding (interaction) of in T cells associated with adhesions
4) Confidence 0.35 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.32 Pain Relevance 0.03
This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion.
Negative_regulation (blocking) of ICAM-1 Binding (interaction) of in T cells associated with adhesions
5) Confidence 0.35 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.32 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox